Notifications
Back

ABOUT

OUR ORIGIN

RADEXEL stands for the convergence of
Radiation and Excellence.

It all began in 2013, inside a small laboratory
at Asan Medical Center in Seoul.
Our journey started with a critical question from the clinical frontline:
"Can cancer treatment be made safer?"

Countless sleepless nights spent refining rough prototypes have culminated in what is now recognized globally as one of the most precise cancer treatment technologies available.
Staying true to our original mission, we continue to strive for perfection—for the sake of every patient.

EST. 2013 | SEOUL ASAN MEDICAL CENTER

WHO WE ARE

Innovating the Future of Cancer Treatment

Radexel is pioneering a fusion solution that combines radiation therapy with advanced magnetic control technology.
We are building an optimized medical device ecosystem tailored to diverse clinical needs: the 'Modular Add-on (MPRT-SD)' for upgrading existing systems,
the 'Integrated All-in-One (MPRT-IS)' for complete treatment solutions,
and the 'Robotic System (MPRT-RB)' for precise, targeted therapy.

Cost Efficiency & Accessibility
Maximizing Efficiency

We aim to resolve the challenges of high acquisition costs and limited efficiency associated with modern radiation therapy systems. High costs often restrict patient access to necessary treatments. Radexel is driving technological innovation to enhance cost-efficiency, creating an environment where more patients can receive timely and effective care.

Precision & Safety
Targeting via Magnetic Control

Our Magnetic-Radiation Fusion Technology controls the path and distribution of radiation beams using magnetic fields. This system is designed to concentrate the radiation dose precisely on the tumor while minimizing exposure to surrounding healthy organs. We aim to deliver superior precision compared to conventional methods while alleviating the economic burden on patients.

Technology Leadership
Robust IP Portfolio & Validation

Radexel holds the world’s largest portfolio of foundational patents in magnetic-radiation fusion therapy. We have successfully completed prototype development and pre-clinical validation, proving the feasibility of our technology. As a global frontrunner, we are now focused on refining and advancing this cutting-edge technology.

Up to
0%*
Dose Reduction Healthy Tissue Sparing
 
0+
Global Patents Core Patents Held
 
0M+
Total Funding($) Investment & R&D Grants
* Dose reduction data is based on phantom studies and pre-clinical trials comparing Radexel’s magnetic control technology with conventional photon beam therapy (IMRT).

Our Footsteps

HISTORY

2025
  • Awarded Radiation Fusion Industry Support Grant
    (Project Scale: KRW 1.52 billion)
  • Opened Tech Center
    (Established GMP Manufacturing Facility)
2024
  • Opened Radexel Seoul Center Software Research Lab
2023
  • Awarded AI-based Medical Device Commercialization Project Grant
    (Project Scale: KRW 2.23 billion)
2022
  • Completed 1st Round of Investment
  • Established Corporate R&D Center
    (Yongsan Central Park Tower)
  • Completed Radiation Shielding Laboratory
    (Located within Kangwon National University Hospital)
2021
  • Opened Radexel Seoul Center
    (Yongsan Central Park Tower)
  • Selected for ICT Innovation Voucher Support Project
    (Project Scale: KRW 520 million)
2019
  • Executed Technology Transfer
    (From Asan Medical Center to Radexel Inc.)
2018
  • Founded Radexel Inc.
2016
  • Registered First Patent
    (No. 10-1689130: Radiation Therapy Apparatus Using Magnetic Fields)
2013 - 2014
  • 2014: Conducted Pre-clinical Animal Trials for Magnetic-Radiation Fusion Technology
  • 2013: Initiated Basic Development & Verification of Magnetic-Radiation Fusion Technology at Asan Medical Center